HEMOCHRON JR. MICROCOAGULATION ACT PLUS TEST JACT+

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed with the FDA on 2015-09-03 for HEMOCHRON JR. MICROCOAGULATION ACT PLUS TEST JACT+ manufactured by Accriva Diagnostics.

Event Text Entries

[25913657] This mdr submitted on (b)(6) 2015 references accriva complaint number (b)(4). The serial number of the hemochron signature elite instrument used during this procedure and reported as a child under this mdr is (b)(4) and references accriva complaint number (b)(4). Method: actual device not evaluated. Process evaluation performed. No other ncrs or other anomalies related to the complaint were identified. Trend noted for the product but no trend for the lot in question. No capa. Results: no results available since no evaluation was performed. Conclusion: device not returned. The hemochron signature elite (serial number (b)(4)) used during this case was been returned for evaluation. Accruva has requested all data required for form 3500a.
Patient Sequence No: 1, Text Type: N, H10


[25913658] Healthcare professional reported a lower than expected reading with a hemochron signature elite and act plus system. A (b)(6) male patient was receiving iv heparin during a 6-vessel cabg. The target act was greater than 400 seconds. The hemochron signature elite and act plus system reported an act result of 368 seconds, which was lower than expected. The perfusionist questioned the result and repeated the test on a second hemochron signature elite instrument (serial number (b)(4)) and the result was 434 seconds, which was as expected. The procedure was completed without adverse events. Whole blood samples were obtained from a flowing line on bypass and no waste was required, which is consistent with the instructions for use. Both electronic and liquid quality controls passed.
Patient Sequence No: 1, Text Type: D, B5


[73850971] This mdr follow up #1 submitted on 10/20/2015. References accriva complaint number (b)(4). This report provides the results of 2015-css-047, which attempted to reproduce the customer complaint of inconsistent act results with this cuvette lot of jact+. Reserve sample from same lot, no failure detected. Whole blood samples from three normal donor were tested at final heparin concentrations of 0, 3. 3 and 5. 0 units/ml with 10 replicates.
Patient Sequence No: 1, Text Type: N, H10


[73850972] Follow up #1.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3002721930-2015-00004
MDR Report Key5060318
Date Received2015-09-03
Date of Report2015-08-06
Date of Event2015-08-06
Date Mfgr Received2015-10-19
Device Manufacturer Date2015-06-01
Date Added to Maude2015-09-08
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactJON MCDERMED
Manufacturer Street6260 SEQUENCE DR
Manufacturer CitySAN DIEGO CA 92121
Manufacturer CountryUS
Manufacturer Postal92121
Manufacturer Phone8582632490
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameHEMOCHRON JR. MICROCOAGULATION ACT PLUS TEST
Generic NameTEST, TIME, ACTIVATED CLOTTING TIME
Product CodeJBP
Date Received2015-09-03
Model NumberJACT+
Catalog NumberJACT+
Lot NumberF5JAC508
Device Expiration Date2016-09-30
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerACCRIVA DIAGNOSTICS
Manufacturer AddressSAN DIEGO CA 92128 US 92128


Patients

Patient NumberTreatmentOutcomeDate
10 2015-09-03

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.